SCOPUS 정보 검색 플랫폼

Drugs

Volumn 64, Issue 10, 2004, Pages 1133-

Palonosetron

(2) Labianca, Roberto M a Tonini, Giuseppe b

a OSPEDALI RIUNITI (Italy)

b UNIVERSITY CAMPUS BIO MEDICO (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOLASETRON MESILATE; PALONOSETRON;

CHEMOTHERAPY INDUCED EMESIS; COMPARATIVE STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; NAUSEA AND VOMITING; NOTE; PRACTICE GUIDELINE; SINGLE DRUG DOSE;

EMESIS;

EID: 2942517913 PISSN: 00126667 EISSN: None Source Type: Journal
DOI: 10.2165/00003495-200464100-00007 Document Type: Note

Times cited : (1)

References (4)

1
- 0344412945
- Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron
- Dec 1
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003 Dec 1; 98 (11): 2473-82
- (2003) Cancer , vol.98 , Issue.11 , pp. 2473-2482
- Eisenberg, P.¹ Figueroa-Vadillo, J.² Zamora, R.³

2
- 10744219621
- Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
- Oct
- Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003 Oct; 14 (10): 1570-7
- (2003) Ann Oncol , vol.14 , Issue.10 , pp. 1570-1577
- Gralla, R.¹ Lichinitser, M.² Van Der Vegt, S.³

3
- 2942571244
- Palonosetron (PALO) is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
- June 18-21; Berlin
- Aapro MS, Bertoli L, Lordick K, et al. Palonosetron (PALO) is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) [abstract]. Multinational Association of Supportive Care in Cancer (MASCC)/International Society for Oral Oncology (ISOO) 15th International Symposium on Supportive Care in Cancer; 2003 June 18-21; Berlin
- (2003) Multinational Association of Supportive Care in Cancer (MASCC)/International Society for Oral Oncology (ISOO) 15th International Symposium on Supportive Care in Cancer
- Aapro, M.S.¹ Bertoli, L.² Lordick, K.³

4
- 0347186065
- Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT(3) receptor antagonist
- abstract no. 3041. Plus poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago
- Cartmell AD, Ferguson S, Yanagihara R, et al. Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT(3) receptor antagonist [abstract no. 3041]. Proc Am Soc Clin Oncol 2003; 22: 756. Plus poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago
- (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 756
- Cartmell, A.D.¹ Ferguson, S.² Yanagihara, R.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.